By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Mentor Capital, Inc. (OTCMKTS:MNTR) reports that its proprietary Cancer Immunotherapy Index appreciated 97.4% during 2013. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the same 2013 annual period the biotech indices averaged a 54.8% gain (see also Mentor Capital, Inc.).
Inovio (481%), Provectus (330%) and Celldex (261%) have led the sector in gains during the January thru September 2013 period. Celldex ($2.0 Billion) represents 39% of the market capitalization of the fifteen member Cancer Immunotherapy Index which has a combined total share value of $5.1 Billion.
The Mentor Capital Cancer Immunotherapy Index companies and their performance for the twelve months of 2013 follow: Galena Biopharma Corporation (NASDAQ:GALE) +224.18%, NewLink Genetics Corporation (NASDAQ:NLNK) +76.08%, Vical Incorporated (NASDAQ:VICL) -59.45%, Inovio Pharmaceuticals, Inc. (NYSEMKT:INO) +480.58%, Dendreon (NASDAQ:DNDN) -43.48%, Immunocellular Therapeutics, Ltd. (NYSE MKT:IMUC) -51.56%, Agenus (NASDAQ:AGEN) -35.61, Oncothyreon (NASDAQ:ONTY) -8.33%, Biovest International (OTCMKTS:BVTIQ) -100.00%, Celldex Therapeutics (NASDAQ:CLDX) +260.80%, Northwest Biotherapeutics (NASDAQ:NWBO) +45.85%, CEL - SCI Corp. (NYSEMKT:CVM) -78.15% , Generex Biotechnology (OTCBB:GNBT) +14.40% as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express, Provectus Pharmaceuticals, Inc. (OTCMKTS:PVCT) +330.36% and Advaxis, Inc. (OTCBB:ADXSD) +13.07 - all for an average 2013 annual gain of +97.40%.
Keywords for this news article include: Biotechnology, Cancer, Genetics, Oncology, Immunotherapy, Immunomodulation, Mentor Capital Inc..
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC